ReoPro Post-Approval Trials Have Cost $250 Mil. Including J&J Stent Work
Executive Summary
Centocor has spent about $250 mil. on post-approval trials since 1995 to demonstrate the efficacy of ReoPro in combination with coronary stents and to generate outcomes data for the antiplatelet monoclonal, Centocor CEO David Holveck reported at the recent Wharton New Ventures in Health Care Conference.
You may also be interested in...
Lehigh Valley Hospital Negotiating Risk Contracts With Manufacturers
Lehigh Valley Hospital is in negotiations with two manufacturers for contracts that would include guarantees related to reduced lengths of stay
Lehigh Valley Hospital Negotiating Risk Contracts With Manufacturers
Lehigh Valley Hospital is in negotiations with two manufacturers for contracts that would include guarantees related to reduced lengths of stay
Centocor Remicade RA Launch Will Get J&J Support, Ultram Experience
Centocor will have the support and experience of J&J's pain product marketing for the expansion of Remicade into the rheumatoid arthritis market.